---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-121533"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T21:00:11.512104+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration

## Summary
- Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.
- Completed IPO in Oct 2024: 6.82M shares at $11.00, gross proceeds $82.1M (including partial underwriter option).
- Entered strategic research collaboration with BioMarin valued at over $370M in milestones and royalties.
- Phase 1 SAD portion completed; safety data expected Q1 2025, MAD biomarker data in H2 2025.
- Cash $2.5M as of Sep 30, 2024; pro forma with IPO proceeds well-positioned to support development.

## SEC filing metadata
- accession: 0001104659-24-121533
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/0001104659-24-121533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/tm2428967d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-121533
- JSON: https://secwatch.observer/filing/0001104659-24-121533.json
- Plain text: https://secwatch.observer/filing/0001104659-24-121533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.